Palisade Bio, Inc. (PALI)

Palisade Bio Statistics

Total Valuation

Palisade Bio has a market cap or net worth of $2.94 million. The enterprise value is -$6.73 million.

Market Cap	2.94M
Enterprise Value	-6.73M

Important Dates

The last earnings date was Monday, March 24, 2025, after market close.

Earnings Date	Mar 24, 2025
Ex-Dividend Date	n/a

Share Statistics

Palisade Bio has 4.40 million shares outstanding. The number of shares has increased by 210.62% in one year.

Current Share Class	4.40M
Shares Outstanding	4.40M
Shares Change (YoY)	+210.62%
Shares Change (QoQ)	+44.03%
Owned by Insiders (%)	0.50%
Owned by Institutions (%)	2.29%
Float	4.09M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.25
P/TBV Ratio	0.39
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.24, with a Debt / Equity ratio of 0.02.

Current Ratio	3.24
Quick Ratio	3.05
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-1,238.25

Financial Efficiency

Return on equity (ROE) is -153.55% and return on invested capital (ROIC) is -96.02%.

Return on Equity (ROE)	-153.55%
Return on Assets (ROA)	-74.50%
Return on Invested Capital (ROIC)	-96.02%
Return on Capital Employed (ROCE)	-194.39%
Revenue Per Employee	n/a
Profits Per Employee	-$1.60M
Employee Count	9
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -88.59% in the last 52 weeks. The beta is 1.38, so Palisade Bio's price volatility has been higher than the market average.

Beta (5Y)	1.38
52-Week Price Change	-88.59%
50-Day Moving Average	1.00
200-Day Moving Average	2.67
Relative Strength Index (RSI)	31.08
Average Volume (20 Days)	704,009

Short Selling Information

The latest short interest is 291,489, so 6.63% of the outstanding shares have been sold short.

Short Interest	291,489
Short Previous Month	148,042
Short % of Shares Out	6.63%
Short % of Float	7.13%
Short Ratio (days to cover)	0.43

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-14.86M
Pretax Income	-13.50M
Net Income	-14.44M
EBITDA	-14.86M
EBIT	-14.86M
Earnings Per Share (EPS)	-$10.19

Balance Sheet

The company has $9.83 million in cash and $169,000 in debt, giving a net cash position of $9.66 million or $2.20 per share.

Cash & Cash Equivalents	9.83M
Total Debt	169,000
Net Cash	9.66M
Net Cash Per Share	$2.20
Equity (Book Value)	7.49M
Book Value Per Share	2.71
Working Capital	7.26M

Cash Flow

Operating Cash Flow	-12.19M
Capital Expenditures	n/a
Free Cash Flow	-12.19M
FCF Per Share	-$2.77

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Palisade Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-210.62%
Shareholder Yield	-210.62%
Earnings Yield	-491.89%
FCF Yield	-415.41%

Analyst Forecast

The average price target for Palisade Bio is $23.00, which is 3,345.18% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$23.00
Price Target Difference	3,345.18%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-17.84%

Stock Splits

The last stock split was on April 8, 2024. It was a reverse split with a ratio of 0.0666667:1.

Last Split Date	Apr 8, 2024
Split Type	Reverse
Split Ratio	0.0666667:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	1